Navigation Links
DDP733 in Medical Technology

Dynogen's DDP733 Reduces Reflux in Phase 1b GERD Study

- DDP733 reduces esophageal reflux - Waltham, Mass., June 7, 2007 – Dynogen Pharmaceuticals, Inc. reported positive results of its randomized, double-blind, placebo-controlled Phase 1b trial of DDP733 for gastroesophageal reflux disease (GERD). The study was designed to demonstrate proof-...

Dynogen Reports Positive Results in Phase 1B GERD Study

...double-blind, placebo-controlled Phase 1b trial of ddp733 for gastroesophageal reflux disease (GERD). The st...y was designed to demonstrate proof-of-concept for ddp733 as a treatment for nocturnal GERD (NGERD). The 0.5 mg dose of ddp733 achieved statistical significance over placebo on ...
DDP733 in other areas

Dynogen Presents Results Of Its Positive Phase 2a IBS-c Study With DDP733

Dynogen Pharmaceuticals, Inc. announced the presentation of positive results from its Phase 2a clinical trial for DDP733 (pumosetrag) as a treatment for irritable ...

Dynogen's Prokinetic Drug, DDP733, Enters Phase 2b For Irritable Bowel ...

Dynogen Pharmaceuticals, Inc. announced that the first patients have been dosed in a Phase 2b trial of DDP733 (pumosetrag) as a treatment for irritable bowel ...

Dynogen to Receive Two Key European Patents for DDP733

Dynogen is also studying DDP733 in a Phase 1b translational medicine clinical ... Preclinical studies of DDP733 established the compound's prokinetic properties ...

Portfolio Company News

DDP733 to enter Phase 2b in the Fourth Quarter ... DDP733 achieved an overall clinical response rate of 54% in patients receiving a ...

Press Release: Dynogen Pharmaceuticals Reports Positive Results In ...

Press Release: Dynogen Pharmaceuticals Reports Positive Results In Phase 2 IBS-c ... DDP733 achieved an overall clinical response rate of 54% in patients receiving a ...

Dynogen Pharmaceuticals, Inc. Reports Positive Results In Phase 2 IBS-c ...

DDP733 achieved an overall clinical response rate of 54% in patients receiving a ... Preclinical studies of DDP733 established the compound's prokinetic properties ...
Other Tags
(Date:7/22/2014)... the Clean Plate Club you eat pretty much everything ... A new Cornell University study shows that the average adult ... or her plate. "If you put it on ... Ph.D., author of the forthcoming book, Slim by Design, Professor ... Lab. , Wansink and co-author Katherine Abowd Johnson analyzed 1179 ...
(Date:7/22/2014)... Legislation backed by the drugstore lobby ... Act of 2014”) championing so-called “any willing pharmacy” ... availability of lower cost preferred pharmacy networks and ... next 10 years, according to new research from ... Management Association (PCMA). , The drugstore lobby targets ...
(Date:7/22/2014)... -- New guidelines on cholesterol treatment and cardiovascular risk ... risk of dying from atherosclerotic cardiovascular disease or of ... with a similar risk profile (based on age, smoking ... of this finding for when and how aggressively to ... Journal of Men,s Health , a peer-reviewed publication ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... (HealthDay News) -- One of the largest studies ever ... has uncovered 83 new sites on chromosomes that harbor ... by an international team of researchers, now bring the ... disorder to 108. Although these schizophrenia-associated genes ... to predict who will or will not develop the ...
Breaking Medicine News(10 mins):Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2
(Date:7/22/2014)... the National Institute of Standards and Technology (NIST), ... dramatically improved technique for analyzing biological cells and ... new NIST technique is an advanced form of ... that delivers signals that are 10,000 times stronger ... times stronger than obtained from comparable "coherent Raman" ...
(Date:7/22/2014)... Stem cells offer much promise for treating damaged organs ... survival is poor, limiting their effectiveness. New methods are ... optimize their therapeutic function after transplantation, as described in ... a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ... Open Access website . , In ...
(Date:7/22/2014)... Cambridge, MA and Shenzhen, China July 22, ... Tech), a subsidiary of BGI, the world,s largest ... a new human whole exome sequencing service based ... service includes in-depth bioinformatics analysis and SNP validation, ... 31, 2014. , Complete Genomics, highly regarded ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3BGI Tech launches human whole exome sequencing service on complete genomics' advanced platform 2
Other Contents